Blueprint’s voyage ends in disaster

Blueprint shares dropped 19% in early trade; the surprise failure of the late-line Gist study effectively limits the drug to a tiny niche. All further work in Gist has been abandoned, executives said today, as they admitted that FDA approval in a fourth-line setting, due next month, was now very unlikely to happen.